Imad Tarhoni
Overview
Explore the profile of Imad Tarhoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos M, Assad N, Batist G, et al.
Clin Cancer Res
. 2024 Dec;
31(3):439-456.
PMID: 39625818
With immuno-oncology becoming the standard of care for a variety of cancers, identifying biomarkers that reliably classify patient response, resistance, or toxicity becomes the next critical barrier toward improving care....
2.
Anderson K, Beckmann C, Heermant S, Ko F, Dulion B, Tarhoni I, et al.
JBMR Plus
. 2023 Nov;
7(11):e10819.
PMID: 38025036
An increasing number of patients with type 2 diabetes (T2DM) will require total joint replacement (TJR) in the next decade. T2DM patients are at increased risk for TJR failure, but...
3.
Auger C, Moudgalya H, Neely M, Stephan J, Tarhoni I, Gerard D, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190187
Due to poor compliance and uptake of LDCT screening among high-risk populations, lung cancer is often diagnosed in advanced stages where treatment is rarely curative. Based upon the American College...
4.
Ash M, Bhimalli P, Cho B, Mattamana B, Gambut S, Tarhoni I, et al.
Cell Rep
. 2022 Dec;
41(11):111799.
PMID: 36493786
Although vaccination efforts have expanded, there are still gaps in our understanding surrounding the immune response to SARS-CoV-2. Measuring IgG Fc glycosylation provides insight into an infected individual's inflammatory state,...
5.
Fhied C, Tarhoni I, Gerard D, Lewin G, Moudgalya H, Schneider J, et al.
J Vis Exp
. 2022 Mar;
(180).
PMID: 35253789
Multiplex technologies for interrogating multiple biomarkers in concert have existed for several decades; however, methods to evaluate multiple epitopes on the same analyte remain limited. This report describes the development...
6.
Yun N, Rouhani S, Bestvina C, Ritz E, Gilmore B, Tarhoni I, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33804721
Background: First-line treatment for patients with non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor () mutation is a tyrosine kinase inhibitor (TKI). Despite higher response rates...
7.
Tarhoni I, Wakefield C, Kollipara R, Fidler M, Batus M, Bonomi P, et al.
J Immunol Methods
. 2021 Jan;
490:112956.
PMID: 33434603
Background: Durable tumor regressions are observed in a subset of advanced-stage non-small cell lung cancer (NSCLC) patients receiving PD-1/-L1 targeted immune checkpoint inhibitors (or 'immunotherapy') alone or in combination with...
8.
Tarhoni I, Fhied C, Pool M, Liptay M, Bonomi P, Seder C, et al.
J Immunoassay Immunochem
. 2018 Jan;
39(1):84-98.
PMID: 29309212
Background: Angiogenesis is associated with tumor progression in a range of malignancies. Herein, we develop custom immunobead assays for several mechanistically important targets and evaluated these against sera from cohorts...
9.
Seder C, Kubasiak J, Pithadia R, Basu S, Fhied C, Tarhoni I, et al.
Ann Thorac Surg
. 2015 Jul;
100(2):429-36.
PMID: 26138771
Background: Low-dose computed tomography (CT) lung cancer screening is known to have a high false positive rate. This study aims to survey biomarkers of angiogenesis for those capable of assigning...